中證網訊 西(xi)南(nan)藥業(ye)(600666)1月22日晚間公告表示, 2015年1月22日(ri),公司(si)本(ben)次重大(da)資(zi)(zi)產(chan)重組的交易對方之(zhi)一哈(ha)爾(er)濱工(gong)(gong)(gong)業(ye)(ye)(ye)(ye)大(da)學實(shi)業(ye)(ye)(ye)(ye)開發(fa)總公司(si)(以(yi)下簡(jian)稱(cheng):哈(ha)工(gong)(gong)(gong)大(da)實(shi)業(ye)(ye)(ye)(ye)公司(si))的控股(gu)股(gu)東哈(ha)爾(er)濱工(gong)(gong)(gong)業(ye)(ye)(ye)(ye)大(da)學收到中華人民共和國工(gong)(gong)(gong)業(ye)(ye)(ye)(ye)和信(xin)息(xi)化部(以(yi)下簡(jian)稱(cheng):工(gong)(gong)(gong)信(xin)部)下發(fa)的《關于哈(ha)爾(er)濱工(gong)(gong)(gong)業(ye)(ye)(ye)(ye)大(da)學實(shi)業(ye)(ye)(ye)(ye)開發(fa)總公司(si)與西南藥業(ye)(ye)(ye)(ye)股(gu)份(fen)有限公司(si)資(zi)(zi)產(chan)重組的批復》
工(gong)(gong)信(xin)部根據《財(cai)政部關于批復(fu)同(tong)意哈(ha)爾濱(bin)工(gong)(gong)業(ye)大(da)學實業(ye)開發總公(gong)(gong)司(si)與上(shang)市公(gong)(gong)司(si)西南(nan)藥(yao)業(ye)股份有(you)限公(gong)(gong)司(si)資產重組的(de)函》,批復(fu)如(ru)下:一、同(tong)意哈(ha)爾濱(bin)工(gong)(gong)業(ye)大(da)學下屬哈(ha)工(gong)(gong)大(da)實業(ye)公(gong)(gong)司(si)與西南(nan)藥(yao)業(ye)的(de)資產重組方案(an)。二、同(tong)意哈(ha)工(gong)(gong)大(da)實業(ye)公(gong)(gong)司(si)以所持哈(ha)爾濱(bin)奧(ao)瑞德光電(dian)技術股份有(you)限公(gong)(gong)司(si)8.93%的股權(quan)認購西南(nan)藥業非公開(kai)發行的股份4987.69萬股(gu),股(gu)份發行價格不(bu)低于西南(nan)藥(yao)業第(di)七屆(jie)董(dong)事會(hui)第(di)二十四(si)次會(hui)議決議公告(gao)日前20個交易日股票均價(經除息調整),即7.42元/股。(申玉(yu)彬)